_what-makes-md-anderson-1-preview-1.jpg "What makes MD Anderson #1? from a d anderson cancer center houston tx Video Screenshot Preview 1")
Gallery_what-makes-md-anderson-1-preview-3.jpg "What makes MD Anderson #1? from a d anderson cancer center houston tx Video Screenshot Preview 3")
Gallery_what-makes-md-anderson-1-preview-hqdefault.jpg "What makes MD Anderson #1? from a d anderson cancer center houston tx Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 2 minutes 10 seconds
👁 View: 6.1K times
Play Audio:👁 View: 6.1K times
Description:
MD Anderson Cancer Center
MD Anderson Cancer Center
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_music-in-medicine-amp-concerts-in-the-park-be-my-valentine.webp "MD Anderson Cancer Center")
_music-in-medicine-amp-concerts-in-the-park-the-mozart-effect.webp "MD Anderson Cancer Center")
_vali-a-papadimitrakopoulou-md-and-fabrice-denis-md-phd-on-lung-cancer-improving-os-with-an-app.webp "Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Fabrice Denis, MD, PhD, of the Institut Inter-regional de Cancérologie Jean Bernard, discuss findings from a phase III trial on an app used between visits for early detection of symptomatic relapse and complications in high-risk lung cancer patients (Abstract LBA9006).")
⏲ 3 min 81 sec ✓ 08-Jun-2016
_chronic-lymphocytic-leukemia-survivor-gives-back-at-md-anderson-league-city.webp "MD Anderson Cancer Center")
⏲ 1 minute 33 seconds 👁 631
_cml-the-current-landscape-an-interview-with-dr-jorge-cortes.webp "The National CML (Chronic Myelogenous Leukemia) Society sits down with one of the leading Key Opinion Leaders/Specialists in the treatment of CML to discuss the latest trends and developments for the CML community.nnDr. Jorge Cortes MD is..nnHead, CML SectionnDepartment of LeukemianM.D. Anderson Cancer CenternThe University of Texas Medical CenternHouston, TexasnnMedical Advisor to the National CML SocietynnThe National CML (Chronic Myelogenous Leukemia) Society serves the CML community in the U")
_your-first-appointment-at-md-anderson.webp "MD Anderson Cancer Center")
_why-you-should-start-your-cancer-treatment-at-md-anderson.webp "MD Anderson Cancer Center")
_anthony-j-olszanski-rph-md-and-michael-a-davies-md-phd-on-the-combi-d-study-for-cutaneous-melanoma.webp "Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Michael A. Davies, MD, PhD, of the University of Texas MD Anderson Cancer Center, discuss this phase III study of dabrafenib plus trametinib vs dabrafenib monotherapy in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma (Abstract 9502).")
⏲ 2 min 85 sec ✓ 08-Jun-2016
_music-in-medicine-amp-concerts-in-the-park-be-my-valentine.jpg)
_music-in-medicine-amp-concerts-in-the-park-the-mozart-effect.jpg)
_vali-a-papadimitrakopoulou-md-and-fabrice-denis-md-phd-on-lung-cancer-improving-os-with-an-app.jpg)
_chronic-lymphocytic-leukemia-survivor-gives-back-at-md-anderson-league-city.jpg)
_cml-the-current-landscape-an-interview-with-dr-jorge-cortes.jpg)
_your-first-appointment-at-md-anderson.jpg)
_why-you-should-start-your-cancer-treatment-at-md-anderson.jpg)
_anthony-j-olszanski-rph-md-and-michael-a-davies-md-phd-on-the-combi-d-study-for-cutaneous-melanoma.jpg)
![[+]](/images/menu.gif){kind=small}